- Report
- February 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- October 2023
- 180 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Report
- July 2022
- 100 Pages
Global
From €2650EUR$2,750USD£2,279GBP
- Report
- January 2024
- 78 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- September 2019
Global
From €5174EUR$5,370USD£4,451GBP
Bradycardia is a type of cardiac arrhythmia characterized by a slow heart rate. Bradycardia drugs are used to treat this condition and are part of the larger cardiovascular drug market. These drugs work by increasing the heart rate and restoring normal rhythm. Commonly used bradycardia drugs include beta-blockers, calcium channel blockers, and pacemaker drugs. Beta-blockers are used to reduce the workload on the heart and slow the heart rate. Calcium channel blockers are used to reduce the force of contraction of the heart muscle and slow the heart rate. Pacemaker drugs are used to stimulate the heart and restore normal rhythm.
The bradycardia drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Other companies include AstraZeneca, Bristol-Myers Squibb, and Boehringer Ingelheim. Show Less Read more
